The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma

Abstract Background Glioblastoma recurrence after treatment with the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is characterized by a highly infiltrative and malignant behavior that renders surgical excision and chemotherapy ineffective. It has been demonstrated that anti-VE...

Full description

Bibliographic Details
Main Authors: Giovanni Luca Gravina, Andrea Mancini, Francesco Marampon, Alessandro Colapietro, Simona Delle Monache, Roberta Sferra, Flora Vitale, Peter J. Richardson, Lee Patient, Stephen Burbidge, Claudio Festuccia
Format: Article
Language:English
Published: BMC 2017-01-01
Series:Journal of Hematology & Oncology
Subjects:
Glioblastoma
CXCR4
Bevacizumab
Sunitinib
Online Access:http://link.springer.com/article/10.1186/s13045-016-0377-8

Internet

http://link.springer.com/article/10.1186/s13045-016-0377-8

Similar Items